-
公开(公告)号：US07282205B2
公开(公告)日：2007-10-16
申请号：US10494676
申请日：2002-11-07
IPC分类号： A61K39/395 , C07K16/00 , C12N15/00 , C12P21/06 , G01N33/53
CPC分类号： C07K16/1009 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/565
摘要： Chimpanzee monoclonal antibodies and antigen binding fragments including a γ1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of a subject with hepatitis A virus, and in screening for agents that affect HAV.
摘要翻译： 本文公开了黑猩猩单克隆抗体和包含结合甲型肝炎病毒（HAV）抗原的γ1链CDR3区域的抗原结合片段。 抗体中和HAV。 还公开了在检测甲型肝炎病毒中使用这些抗体和抗原结合片段的方法，用甲型肝炎病毒抑制受试者的感染，以及筛选影响HAV的药剂。
-
公开(公告)号：US06423318B1
公开(公告)日：2002-07-23
申请号：US09653499
申请日：2000-08-31
IPC分类号： C12N700
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K2039/5254 , A61K2039/542 , A61K2039/545 , C12N7/00 , C12N2770/32421 , C12N2770/32422 , C12N2770/32432 , C12N2770/32434 , Y02A50/464
摘要： A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation, methods for adapting HAV to growth in MRC-5, vaccine compositions and method of vaccinating humans against HAV infection.
摘要翻译： 适用于MRC-5细胞生长的活A型甲型肝炎病毒，其中HAV优选特征在于对于没有灭活的人和动物的有效疫苗施用的合适的衰减特征在于，适于使HAV适应MRC-5生长的方法，疫苗组合物和疫苗接种方法 人类对HAV感染。
-
公开(公告)号：US06180110B2
公开(公告)日：2001-01-30
申请号：US08397232
申请日：1995-04-17
IPC分类号： A61K3929
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K2039/5254 , A61K2039/542 , A61K2039/545 , C12N7/00 , C12N2770/32421 , C12N2770/32422 , C12N2770/32432 , C12N2770/32434 , Y02A50/464
摘要： A live hepatitis A virus (HAV) adapted to grow in MRC-5 cells is described, the HAV preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation. Methods for adapting HAV to grow in MRC-5 cells, vaccine compositions comprising the attenuated HAV, and methods of vaccinating humans against HAV infection are also described.
摘要翻译： 描述了适于在MRC-5细胞中生长的活A型甲型肝炎病毒（HAV），HAV优选特征在于对于人和动物没有失活的有效疫苗施用的合适的衰减。 还描述了使HAV在MRC-5细胞中生长的方法，包含减毒的HAV的疫苗组合物和接种人抵抗HAV感染的方法。
-
公开(公告)号：US6156499A
公开(公告)日：2000-12-05
申请号：US142239
申请日：1998-09-03
IPC分类号： G01N33/576 , C12Q1/70
CPC分类号： G01N33/5768 , Y10S436/82
摘要： The present invention discloses methods for detecting antibodies to HAV 3C proteinase. These methods can distinguish an individual with a natural infection from one who has been vaccinated with an inactivated vaccine and are thus of utility in the diagnosis of hepatitis A in situations in which vaccination is widespread.
摘要翻译： PCT No.PCT / US97 / 03428 Sec。 371日期：1998年9月3日 102（e）1998年9月3日PCT 1997年3月13日PCT PCT。 公开号WO97 / 34136 日期：1997年9月18日本发明公开了检测HAV 3C蛋白酶抗体的方法。 这些方法可以将具有天然感染的个体与已经用灭活疫苗接种的个体进行区分，因此在广泛接种疫苗的情况下可用于诊断甲型肝炎。
-
25.发明授权Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines 失效戊型肝炎病毒的重组蛋白及其在诊断方法和疫苗中的应用
公开(公告)号：US6054567A
公开(公告)日：2000-04-25
申请号：US840316
申请日：1997-04-11
IPC分类号： G01N33/576 , A61K38/00 , A61K39/00 , A61K39/29 , A61P1/16 , A61P31/20 , C07K14/08 , C07K16/10 , C12N5/10 , C12N15/09 , C12N15/51 , C12P21/02 , C12N15/11 , C12N15/00 , C12N15/63 , C12Q1/70
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/28122 , G01N2333/08
摘要： The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
摘要翻译： 本发明涉及在真核表达系统中来自巴基斯坦（SAR-55）的乙型肝炎病毒株的开放阅读框2（ORF-2）蛋白的表达。 表达的蛋白质可以用作诊断免疫测定中的抗原和/或作为免疫原或疫苗以防止乙型肝炎的感染。
-
26.发明授权Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxin 有权中和炭疽保护性抗原（PA）毒素的单克隆抗体公开(公告)号：US08685396B2
公开(公告)日：2014-04-01
申请号：US11793735
申请日：2005-12-21
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , C12N5/10 , G01N33/53
CPC分类号： C07K16/1278 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/622 , C07K2317/76 , C07K2319/00
摘要： The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
摘要翻译： 本发明涉及结合或中和炭疽保护性抗原（PA）毒素的单克隆抗体。 本发明提供了这样的抗体，这种抗体的片段，其保留了炭疽PA毒素结合能力，完全人或人源化抗体保留了炭疽杆菌PA毒素结合能力，以及包含这些抗体的药物组合物。 本发明还提供了编码本发明的抗体的分离的核酸和用其转化的宿主细胞。 另外，本发明提供了使用本发明的抗体和核酸的预防，治疗和诊断方法。
-
公开(公告)号：US08404818B2
公开(公告)日：2013-03-26
申请号：US13038613
申请日：2011-03-02
CPC分类号： C07K16/081 , A61K39/00 , A61K2039/505 , A61K2039/545 , C07K14/005 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2710/24122 , G01N33/56983 , G01N2333/07
摘要： The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
摘要翻译： 本发明涉及结合或中和正痘病毒的单克隆抗体。 本发明提供了这样的抗体，这种抗体保留B5或A33结合能力的片段，完全人抗体保留B5或A33结合能力，以及包含这些抗体的药物组合物。 本发明还提供了编码本发明的抗体的分离的核酸和用其转化的宿主细胞。 另外，本发明提供了使用本发明的抗体和核酸的预防，治疗和诊断方法。
-
公开(公告)号：US08071100B2
公开(公告)日：2011-12-06
申请号：US12528427
申请日：2008-02-21
IPC分类号： A61K39/40
CPC分类号： C07K16/1278 , A61K51/1009 , A61K2039/505 , C07K16/40 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/56911 , G01N33/573 , G01N2333/32 , G01N2333/954 , G01N2469/10
摘要： The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
摘要翻译： 本发明涉及结合或中和炭疽致死因子（LF），水肿因子（EF）和/或保护性抗原（PA）的单克隆抗体。 本发明提供了这样的抗体，这种抗体的保留了炭疽毒素结合能力的片段，完全人或人源化抗体，保留了炭疽毒素结合能力，以及包含这些抗体的药物组合物。 本发明还提供了编码本发明的抗体的分离的核酸和用其转化的宿主细胞。 另外，本发明提供了使用本发明的抗体和核酸的预防，治疗和诊断方法。
-
公开(公告)号：US20100119520A1
公开(公告)日：2010-05-13
申请号：US12528427
申请日：2008-02-21
CPC分类号： C07K16/1278 , A61K51/1009 , A61K2039/505 , C07K16/40 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/56911 , G01N33/573 , G01N2333/32 , G01N2333/954 , G01N2469/10
摘要： The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
摘要翻译： 本发明涉及结合或中和炭疽致死因子（LF），水肿因子（EF）和/或保护性抗原（PA）的单克隆抗体。 本发明提供了这样的抗体，这种抗体的保留了炭疽毒素结合能力的片段，完全人或人源化抗体，保留了炭疽毒素结合能力，以及包含这些抗体的药物组合物。 本发明还提供了编码本发明的抗体的分离的核酸和用其转化的宿主细胞。 另外，本发明提供了使用本发明的抗体和核酸的预防，治疗和诊断方法。
-
30.发明授权Cloned genome of infectious hepatitis C virus strain HC-TN and uses thereof 失效感染性丙型肝炎病毒株HC-TN的克隆基因组及其用途公开(公告)号：US07678569B2
公开(公告)日：2010-03-16
申请号：US12061504
申请日：2008-04-02
申请人： Jens Bukh , Robert H. Purcell , Suzanne U. Emerson , Akito Sakai
发明人： Jens Bukh , Robert H. Purcell , Suzanne U. Emerson , Akito Sakai
CPC分类号： G01N33/5767 , A61K39/12 , A61K39/29 , C07K14/005 , C12N7/00 , C12N2770/24221 , C12N2770/24222 , C12N2770/24234 , G01N2500/04 , G01N2500/10
摘要： Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1a, proteins and polypeptides and fragments thereof. Use of these compositions, and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV are also contemplated.
摘要翻译： 本文描述的实施方案包括编码菌株HC-TN的丙型肝炎病毒，基因型1a，蛋白质和多肽及其片段的核酸序列。 还考虑使用这些组合物和HCV的诊断以及开发用于鉴定HCV的抗病毒剂的筛选测定法。
-
-
-
-
-
-
-
-
-
搜索结果
74 条记录 (耗时 0.044 秒)
